Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

CT2108A and B: New fatty acid synthase inhibitors as antifungal agents.

Laakso JA, Raulli R, McElhaney-Feser GE, Actor P, Underiner TL, Hotovec BJ, Mocek U, Cihlar RL, Broedel SE Jr.

J Nat Prod. 2003 Aug;66(8):1041-6.

PMID:
12932120
2.
3.

Efficacy of the hematoregulatory peptide SK&F 107647 in experimental systemic Candida albicans infections in normal and immunosuppressed mice.

DeMarsh PL, Sucoloski SK, Frey CL, Bhatnagar PK, Koltin Y, Actor P, Petteway SR.

Immunopharmacology. 1994 May-Jun;27(3):199-206.

PMID:
7520890
4.
5.

Aridicins, novel glycopeptide antibiotics. I. Taxonomy, production and biological activity.

Shearer MC, Actor P, Bowie BA, Grappel SF, Nash CH, Newman DJ, Oh YK, Pan CH, Nisbet LJ.

J Antibiot (Tokyo). 1985 May;38(5):555-60.

6.

Enoxacin: a potent inducer of filamentous Escherichia coli cells (a note).

Uri JV, Actor P.

Acta Microbiol Hung. 1985;32(2):197-200.

PMID:
3933273
7.

In vitro experience with cefonicid.

Actor P.

Rev Infect Dis. 1984 Nov-Dec;6 Suppl 4:S783-90.

PMID:
6522920
8.

Antimicrobial activity of SK&F 88070, an expanded-spectrum cephalosporin with high and prolonged levels in blood.

Grappel SF, Phillips L, Dunn GL, Jakas DR, Pitkin D, Actor P.

Antimicrob Agents Chemother. 1984 Jun;25(6):694-700.

9.
10.
11.

Anti-Candida activity of polyoxin: example of peptide transport in yeasts.

Mehta RJ, Kingsbury WD, Valenta J, Actor P.

Antimicrob Agents Chemother. 1984 Mar;25(3):373-4.

12.

Five cephalosporins: pharmacokinetics and their relation to antibacterial potency.

Sohn C, Pitkin D, Grappel S, Zajac I, Actor P, Alexander F, Lentnek A, Wikler M, Stote R, Dubb J.

Clin Ther. 1984;6(4):560-70.

PMID:
6467282
13.

Prophylactic activity of cephalosporins in a mouse model of surgical wound infection.

Grappel SF, Phillips L, Lewis HB, Morgan DG, Actor P.

J Antibiot (Tokyo). 1983 Feb;36(2):161-6. No abstract available.

14.

Effect of interferon inducers and purified mouse interferon on the susceptibility of mice to infection with Listeria monocytogenes.

Grappel SF, Polansky MJ, Actor P.

Adv Exp Med Biol. 1983;162:227-33. No abstract available.

PMID:
6191531
15.

Efficacy of ceftizoxime and related compounds in animals models of infection.

Actor P, Grappel SF.

J Antimicrob Chemother. 1982 Nov;10 Suppl C:81-9. No abstract available.

PMID:
6296033
16.

Aculeacin A resistant mutants of Candida albicans.

Mehta RJ, Nash CH, Grappel SF, Actor P.

J Antibiot (Tokyo). 1982 Jun;35(6):707-11.

17.

Isopycnic separation of Escherichia coli cultures possessing colonization factor antigen I.

Giesa FR, Zajac I, Bartus HF, Actor P.

J Clin Microbiol. 1982 Jun;15(6):1074-6.

19.

Ceftizoxime kinetics and renal handling.

Dubb J, Actor P, Pitkin D, Alexander F, Familiar R, Ehrlich S, Stote R.

Clin Pharmacol Ther. 1982 Apr;31(4):516-21.

PMID:
6277546
20.
21.

Kinetics and renal handling of cefonicid.

Pitkin D, Dubb J, Actor P, Alexander F, Ehrlich S, Familiar R, Stote R.

Clin Pharmacol Ther. 1981 Nov;30(5):587-93.

PMID:
7297018
23.

Cefonicid: a stable beta-lactamase inhibitor.

Mehta RJ, Newman DJ, Bowie BA, Nash CH 3rd, Actor P.

J Antibiot (Tokyo). 1981 Feb;34(2):202-5.

24.

Cefuroxime inhibition of cephalothin hydrolysis by the constitutive beta-lactamase from E. cloacae P99.

Newman DJ, Mehta RJ, Bowie BA, Nash CH 3rd, Actor P.

J Antibiot (Tokyo). 1980 Oct;33(10):1202-3. No abstract available.

25.
26.
27.

Correlation of agar-disc-diffusion tests with minimum inhibitory concentrations of cefonicid (SK&F 75073) and cephalothin.

Grappel SF, Guarini JR, Actor P, Weisbach JA.

J Antibiot (Tokyo). 1980 Jan;33(1):85-7. No abstract available.

28.

Crystallization and antifungal activity of primycin.

Uri JV, Actor P.

J Antibiot (Tokyo). 1979 Nov;32(11):1207-9. No abstract available.

29.

In vitro and in vivo laboratory studies on three hydroxyiminophenylacetyl cephalosporins with particular reference to SK&F 80303, an unusually long-acting cephalosporin.

Uri JV, Actor P, Zajac I, Pitkin DH, Phillips L, Guarini JR, Bartus HF, Polansky TJ, Dunn GL, Hoover JR, Weisbach JA.

J Antibiot (Tokyo). 1979 Nov;32(11):1161-7.

30.
31.

Is Bacillus subtilis ATCC 6633 a beta-lactamase producer?

Uri JV, Actor P, Weisbach JA.

J Antibiot (Tokyo). 1978 Dec;31(12):1304-5. No abstract available.

32.

Distribution in normal and inflammatory tissue of a new semisynthetic cephalosporin, SK&F 75073.

Intoccia AP, Walkenstein SS, Joseph G, Wittendorf R, Girman C, Walz DT, Actor P, Weisbach J.

J Antibiot (Tokyo). 1978 Nov;31(11):1188-94.

33.

A rapid and simple method for detection of beta-lactamase inhibitors.

Uri JV, Actor P, Weisbach JA.

J Antibiot (Tokyo). 1978 Aug;31(8):789-91. No abstract available.

34.

Semisynthetic cephalosporins with antifungal activity: laboratory studies on 2-pyridinethiol 1-oxide cephalosporins.

Uri JV, Actor P, Phillips L, Weisbach JA.

J Antibiot (Tokyo). 1978 Jun;31(6):580-5.

35.

SK&F 75073, new parenteral broad-spectrum cephalosporin with high and prolonged serum levels.

Actor P, Uri JV, Zajac I, Guarini JR, Phillips L, Pitkin DH, Berges DA, Dunn GL, Hoover JR, Weisbach JA.

Antimicrob Agents Chemother. 1978 May;13(5):784-90.

36.

Semiautomated turbidimetric microbiological assay for cefazaflur.

Pitkin DH, Actor P, Baldinus JG, Post A, Weisbach JA.

J Antibiot (Tokyo). 1978 Apr;31(4):359-62.

37.

Biological and chemotherapeutic studies on three semisynthetic cephamycins.

Uri JV, Actor P, Guarini JR, Phillips L, Pitkin D, Demarinis RM, Weisbach JA.

J Antibiot (Tokyo). 1978 Jan;31(1):82-91.

38.

In vitro studies with cefazaflur and other parenteral cephalosporins.

Actor P, Guarini JR, Uri J, Bartus HF, Zajac I, Weisbach JA.

J Antibiot (Tokyo). 1977 Sep;30(9):730-5.

39.

Comparative stability of cephalothin and cefazolin in buffer or human serum.

Pitkin D, Actor P, Filan JJ, White R, Weisbach JA.

Antimicrob Agents Chemother. 1977 Aug;12(2):284-5.

40.

Distribution of sodium cefazolin in serum, muscle, bone marrow, and bone of normal rabbits.

Pitkin DH, Sachs C, Zajac I, Actor P.

Antimicrob Agents Chemother. 1977 Apr;11(4):760-2.

42.

Semisynthetic cephalosporins. Synthesis and structure-activity relationships of 7-sulfonylacetamido-3-cephem-4-carboxylic acids.

DeMarinis RM, Hoover JR, Lam LL, Uri JV, Guarini JR, Phillips L, Actor P, Weisbach JA.

J Med Chem. 1976 Jun;19(6):754-9.

PMID:
781242
45.

Orally active 7-phenylglycyl cephalosporins. Structure-activity studies related to cefatrizine (SK&F 60771).

Dunn GL, Hoover JR, Berges DA, Taggart JJ, Davis LD, Dietz EM, Jakas DR, Yim N, Actor P, Uri JV, Weisbach JA.

J Antibiot (Tokyo). 1976 Jan;29(1):65-80.

46.

Anticestode quinolinehydrazones.

Pellerano C, Savini L, Berkoff CE, Thomas J, Actor P.

Farmaco Sci. 1975 Dec;30(12):965-73.

PMID:
1204834
47.

Laboratory studies with cefatrizine (SK + F 60771), a new broad-spectrum orally-active cephalosporin.

Actor P, Uri JV, Phillips L, Sachs CS, Guarini JR, Zajac I, Berges DA, Dunn GL, Hoover JR, Weisbach JA.

J Antibiot (Tokyo). 1975 Aug;28(8):594-601.

48.

Automated spectrophotometric assay of cefazolin.

Holl WW, O'Brien M, Filan J, Mazeika TR, Post A, Pitkin D, Actor P.

J Pharm Sci. 1975 Jul;64(7):1232-4.

PMID:
1151690
50.

A new parenteral cephalosporin. SK&F 59962: in vitro and in vivo antibacterial activity and serum levels in experimental animals.

Actor P, Uri JV, Guarini JR, Zajac I, Phillips L, Sachs CS, DeMarinis RM, Hoover JR, Weisbach JA.

J Antibiot (Tokyo). 1975 Jun;28(6):471-6.

Supplemental Content

Support Center